Anxiety DisordersDepressive DisordersPTSDEquity and EthicsPsilocybin

People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences

This survey study (n=313) suggests that psychedelic experiences (MDMA, LSD, psilocybin) could reduce symptoms of racial trauma. The participant, 30 days later, slowed moderate reductions in traumatic stress, depression, anxiety, and stress.

Authors

  • Alan Davis
  • Thomas Williams
  • Nathan Sepeda

Published

Drugs Education Prevention and Policy
individual Study

Abstract

This study examined how psychedelics reduced symptoms of racial trauma among black, indigenous, and people of color (BIPOC) subsequent to an experience of racism. A cross-sectional internet-based survey included questions about experiences with racism, mental health symptoms, and acute and enduring psychedelic effects. Changes in mental health were assessed by retrospective report of symptoms in the 30 days before and 30 days after an experience with psilocybin, Lysergic acid diethylamide (LSD), or 3,4-Methyl​enedioxy​methamphetamine (MDMA). We recruited 313 diverse BIPOC in the US and Canada. Results revealed a significant (p < .001) and moderate (d = −.45) reduction in traumatic stress symptoms from before-to-after the psychedelic experience. Similarly, participants reported decreases in depression (p < .001; d = −.52), anxiety (p < .001; d = −.53), and stress (p < .001; d = −.32). There was also a significant relationship (Rc = 0.52, p < .001) between the dimension of acute psychedelic effects (mystical-type, insight, and challenging experiences) and decreases in a cluster of subsequent psychopathology (traumatic stress, depression, anxiety, and stress), while controlling for the frequency of prior discrimination and the time since the psychedelic experience. BIPOC have been underrepresented in psychedelic studies. Psychedelics may decrease the negative impact of racial trauma. Future studies should examine the efficacy of psychedelic-assisted therapy for individuals with a history of race-based trauma.

Available with Blossom Pro

Research Summary of 'People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences'

Introduction

Williams and colleagues frame racial trauma as a form of traumatization arising from repeated experiences of racism and discrimination, which can produce symptoms of traumatic stress, anxiety, and depression. They note that racial trauma is common among Black, Indigenous, and people of colour (BIPOC) in North America and that both overt and subtle forms of racism (including microaggressions, colourblind ideology, and media exposure to police violence) contribute to cumulative psychological harm. The introduction emphasises that conventional PTSD treatments and psychotherapies have limited representation of BIPOC in outcome data, face high dropout in these groups, and do not typically address race-specific mechanisms, creating a need for alternative approaches tailored to racial trauma. This study set out to explore whether naturalistic use of psychedelics is associated with reductions in mental health symptoms among BIPOC who have experienced racial trauma, and to identify acute experiential factors that might account for any observed benefits. Specifically, the investigators asked (1) whether psychedelic use in non-clinical settings relates to changes in traumatic stress, depression, anxiety, and stress following a memorable psychedelic experience after an episode of ethnic discrimination, and (2) which acute effects of the psychedelic experience (mystical-type, insight, or challenging experiences) predict reductions in those symptoms. The authors position this as the first study to examine changes in racial-trauma‑related symptoms following psychedelic use in a diverse BIPOC sample in North America, and suggest it may point to mechanisms relevant for future clinical research.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Create Free AccountAlready have an account? Sign in

Study Details

References (20)

Papers cited by this study that are also in Blossom

Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy

Amoroso, T., Workman, M. · Journal of Psychopharmacology (2016)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD

Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)

108 cited
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety

Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

Davis, A. K., So, S., Lancelotta, R. et al. · The American Journal of Drug and Alcohol Abuse (2019)

113 cited
Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT

Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)

171 cited
Show all 20 references
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)

274 cited
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress dis - order: a randomized phase 2 controlled trial

Ot'alora G, M., Grigsby, J., Poulter, B. et al. · Journal of Psychopharmacology (2018)

182 cited
Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial

Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study

Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)

380 cited

Cited By (23)

Papers in Blossom that reference this study

Insights on Psychedelics: A Systematic Review of Therapeutic Effects

Kugel, J., Laukkonen, R., Yaden, D. B. et al. · Neuroscience and Biobehavioral Reviews (2025)

Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing

Earleywine, M., Falabella, G. S., Oliva, A. B. et al. · Journal of Psychoactive Drugs (2024)

1 cited
An Integrated theory of false insights and beliefs under psychedelics

McGovern, H., Grimmer, H. J., Doss, M. K. et al. · Communications Psychology (2024)

Experiences of psychedelic drug use among people with psychotic symptoms and disorders: Personal growth and mystical experiences

Torre, J. T. L., Gallo, J., Mahammadli, M. et al. · Journal of Psychedelic Studies (2024)

6 cited
Synthetic surprise as the foundation of the psychedelic experience

De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)

Predictors of psychedelic treatment outcomes among special operations forces veterans

Xin, Y., Armstrong, S. B., Averill, L. A. et al. · Psychology of Consciousness Theory Research and Practice (2023)

Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests

Jones, G. M., Nock, M. K. · Frontiers in Psychiatry (2023)

Psychedelic Experiences After Bereavement Improve Symptoms of Grief: The Influence of Emotional Breakthroughs and Challenging Experiences

Low, F., Earleywine, M. · Journal of Psychoactive Drugs (2023)

Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users

Jones, J. L. · Frontiers in Psychiatry (2023)

4 cited
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)

Show all 23 papers
Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms

Nikolaidis, A., Lancelotta, R., Gukasyan, N. et al. · Journal of Affective Disorders (2023)

Acute and enduring effects of naturalistic psychedelic use among Indigenous peoples in Canada and the United States

de la Salle, S., Gran-Ruaz, S., Davis, A. K. et al. · Canadian Psychology (2022)

8 cited
Naturalistic Psychedelic Use: A World Apart from Clinical Care

Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample

Nygart, V., Pommerencke, L. M., Haijen, E. et al. · Journal of Psychopharmacology (2022)

46 cited
Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada

Argento, E., Goldenberg, S., Deering, K. et al. · Drug and Alcohol Dependence (2022)

4 cited
Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controls

Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)

The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of its Provision

Smith, D., Faber, S., Buchanan, N. T. et al. · Frontiers in Psychiatry (2022)

Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia

Glynos, N. G., Pierce, J., Davis, A. K. et al. · Journal of Psychoactive Drugs (2022)

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience

Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)

Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color

Davis, A. K., Xin, Y., Sepeda, N. D. et al. · Chronic Stress (2021)

Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions

Mayer, C. E., LeBaron, V. T., Acquaviva, K. D. · Journal of Psychoactive Drugs (2021)

12 cited
Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment

Healy, C. J., Lee, K. A. · Chronic Stress (2021)

Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination

Halstead, M., Reed, S., Krause, R. et al. · Clinical Case Studies (2021)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in